Payment overview · 2025
General Payments
$33.46
1 reported records · 1 companies
Healthcare provider profile · identity verified
Steffen Villarma, MD
Allopathic & Osteopathic Physicians|Family Medicine · WASHINGTON, PA · NPI 1235692955
Verified facts
What the public records show
CMS Open Payments records show Steffen Villarma, MD received $33.46 in general payments during 2025 across 1 reported records.
Edwards Lifesciences Corporation accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $33.46 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.46 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 350 | 95 |
| Lisinopril | Lisinopril | 328 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 51 |
| Simvastatin | Simvastatin | 191 | 41 |
| Metformin Hcl | Metformin Hcl | 168 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 36 |
| Meloxicam | Meloxicam | 151 | 42 |
| Omeprazole | Omeprazole | 141 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 33 |
| Gabapentin | Gabapentin | 119 | 32 |
| Jardiance | Empagliflozin | 119 | 21 |
| Losartan Potassium | Losartan Potassium | 112 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 48 |
| Furosemide | Furosemide | 93 | 23 |
| Sertraline Hcl | Sertraline Hcl | 89 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 23 |
| Trazodone Hcl | Trazodone Hcl | 84 | 22 |
| Lorazepam | Lorazepam | 79 | 14 |
| Tramadol Hcl | Tramadol Hcl | 69 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 16 |
| Allopurinol | Allopurinol | 63 | 17 |
| Ezetimibe | Ezetimibe | 59 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 18 |
| Potassium Chloride | Potassium Chloride | 55 | suppressed |
| Carvedilol | Carvedilol | 54 | 12 |
| Alendronate Sodium | Alendronate Sodium | 53 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | suppressed |
| Prednisone | Prednisone | 46 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Glipizide | Glipizide | 43 | 12 |
| Bumetanide | Bumetanide | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Etodolac | Etodolac | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 12 |
| Alprazolam | Alprazolam | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 14 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Epinephrine | Epinephrine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.46 · 1 records | Edwards Lifesciences Corporation | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error